


Impact of age on laryngopharyngeal reflux disease presentation: a multi-center prospective study

Jérôme R. Lechien^{1,2,3,4}  · Camille Finck^{2,5} · Kathy Huet² · Mohamad Khalife³ · Anne-Françoise Fourneau³ · Véronique Delvaux² · Myriam Piccaluga² · Bernard Harmegnies² · Sven Saussez^{1,3,4}

Received: 20 April 2017 / Accepted: 8 July 2017 / Published online: 17 July 2017
© Springer-Verlag GmbH Germany 2017

Abstract The objective is to assess the differences in the severity of symptoms, signs, voice quality, and quality of life before and after treatment according to age in suspected laryngopharyngeal reflux (LPR) patients. The design used in this paper is prospective multi-center study. Eighty clinically diagnosed LPR patients with a reflux finding score (RFS) >7 and a reflux symptom index (RSI) >13 were treated with pantoprazole and diet recommendations for 3 months. Patients were subdivided into three groups according their age: group 1 (18–39 years, $N = 21$), group 2 (40–59 years, $N = 31$), and group 3 (≥ 60 years, $N = 28$). RSI, RFS, Voice Handicap Index (VHI), Short Form 36 questionnaire (SF36), aerodynamic, and acoustic measurements were evaluated at baseline and after treatment. The response to the empiric treatment was also assessed.

Significant improvements in RSI, RFS, and VHI were found in all patient groups. The elderly patients showed a significantly lower RSI score than younger subjects ($p = 0.035$) without RFS difference among groups. At baseline, the SF36 score was better in group 3 with respect to social functioning ($p = 0.049$). At the 3-month follow-up, we found significant improvement of acoustic parameters only in the younger age groups (group 1 and group 2). The rate of resistant patients to the empiric treatment was higher in the younger group than in the elderly patient group (42.9 versus 28.6%). Age appears to reduce the subjective LPR symptom perception, leading to a lower rate of uncured patients. The utilization of acoustic parameters as an indicator of treatment effectiveness seems less useful for elderly subjects, probably due to an overlap between an aging voice and LPR.

Bernard Harmegnies and Sven Saussez contributed equally to this work and should be regarded as joint last authors.

✉ Jérôme R. Lechien
jerome.lechien@umons.ac.be

¹ Laboratory of Anatomy and Cell Biology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Avenue du Champ de mars, 6, B7000, Mons, Belgium

² Laboratory of Phonetics, Faculty of Psychology, Research Institute for Language sciences and Technology, University of Mons (UMons), Mons, Belgium

³ Department of Otorhinolaryngology and Head and Neck Surgery, RHMS Baudour, EpiCURA Hospital, Baudour, Belgium

⁴ Department of Otorhinolaryngology and Head and Neck Surgery, CHU Saint-Pierre, CHU de Bruxelles, ULB, Brussels, Belgium

⁵ Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Liege, Liege, Belgium

Keywords Laryngopharyngeal · Reflux · Laryngitis · Voice

Introduction

Laryngopharyngeal reflux disease (LPRD) is an inflammatory condition defined as the back flow of gastric contents into the laryngopharynx which comes in contact with the tissues of the upper aerodigestive tract [1]. In otolaryngologic practice, LPRD afflicts 4–30% of outpatients who visit otolaryngology and head and neck surgery departments and up to 50% of subjects in the voice departments [2, 3]. This pathology typically affects the patients' quality of life via the development of a myriad of symptoms including hoarseness, throat clearing, excess throat mucus, dysphagia, coughing, globus sensation, and, in less than 50%, heartburn or stomach acid reflux [4–6]. The usual laryngostroboscopic signs

suggesting the LPRD diagnosis involve posterior commissure hypertrophy, posterior granulations, hyperemia, diffuse laryngeal edema, sticky mucus, and, in several cases, vocal fold edema [5, 7]. All of these symptoms and signs have been previously described and are easily assessed using the reflux symptom index (RSI >13) and reflux finding score (RFS >7); both clinical scales are used for evaluation of the treatment efficiency, but are also used as a cost-effective method for LPRD diagnosis. Indeed, regarding the many critics of the pH meter (i.e., high false-positive and false-negative rates, interpretation difficulties, inconsistency between pH findings, signs, and symptoms) [8, 9], many authors consider the empirical therapy approach [using a proton pump inhibitor (PPI) twice daily, 12 weeks] as an alternative reliable approach and report similar management than the diagnosis approach based on measurements using a pH meter [10, 11].

To date, it has been long established that the clinical expression of many diseases, such as heart or endocrinal disorders, substantially varies according to the age with unusual symptoms occurring in elderly patients [12, 13]. Thus, the sensation of clinical complaints related to gastroesophageal reflux disease (GERD) may decrease with the elderly [14]. Concerning LPRD, only one study conducted within a Korean population has suggested differences in the clinical presentation of LPRD between age groups, and since elderly patients could present with more symptoms than young patients, this may impact the LPRD-related quality of life [15]. Notwithstanding the results of this paper, the influence of age in LPRD clinical presentation and in the treatment efficiency still remains unclear.

The aim of this study is to assess the differences in the severity of symptoms, signs, voice quality, and quality of life according to the age of the suspected LPRD patients. In addition, we aimed to assess the usefulness of RSI, RFS, and voice quality as outcomes of the empirical treatment efficiency according to the age.

Materials and methods

Subject characteristics

One hundred and twenty-two outpatients with LPRD-related symptoms were recruited at three otolaryngology departments (EpiCURA Baudour & Ath Hospitals, and Liege University Hospital) from September 2013 to April 2016. To be included, patients should have an RSI >13 and an RFS >7; these two thresholds being significantly correlated with a positive double-probe pH monitoring result [16]. To reduce the risk to include subjects with cofactors able to bias the study of the voice quality and the LPRD diagnosis, we adopted strict exclusion criteria's available in Fig. 1. From

these 122 patients, 80 completed the study. We studied three groups of these patients according to their age: these groups included patients from 18 to 39 (Gr1, $N = 21$), 40 to 59 (Gr2, $N = 31$), and more than 60 (Gr3, $N = 28$) years. The choice of these age limits was made according those of the previous studies [15].

The patient characteristics are described in Table 1. All patients were treated using diet and lifestyle behavioral recommendations based on Koufman's work [17] and were prescribed a twice daily pantoprazole (20 mg, 12 weeks). The adherence of diet and behavioral changes was assessed using a point scale with results between 0 (non-adherent) and 10 (fully adherent to the recommendations). At 12 weeks, the patients exhibiting both an RSI ≤ 13 and RFS ≤ 7 were considered to be responder. Following 12 weeks of uncompleted improvement (RSI >13 and/or RFS >7), the twice daily pantoprazole dose was increased (40 mg) for 12 additional weeks. At this time, the uncured patients received a complementary examination [i.e., 24-h pH/impedance monitoring, esophagogastroduodenoscopy (patients with heartburn), etc.] and were considered as resistant to the empiric treatment. To improve patient care [11], we used a clinically validated protocol [10, 11] for the management of the LPRD patients (Fig. 1). This study was approved by the local ethics committee (Ref.2015/99-B707201524621).


Clinical evaluations, subjective voice assessments, and quality of life

All patients fulfilled the French version of the RSI score [18] at baseline and at the end of the empiric treatment. The RFS evaluation was made using video laryngostroboscopy (StrobeLED-CLL-S1, Olympus Corporation, Hamburg, Germany) in a blind manner with regard to the patient complaints (RSI). Specifically, particular attention was given when evaluating the vocal fold edema and trophicity regarding the risk of aging voice occurrence in elderly patients. Subjects also completed the Voice Handicap Index (VHI) [19] and the Short Form 36 Health Survey (SF-36) at baseline and after treatment.

Objective voice quality measurements

Currently, two main approaches exist to objectively assess voice quality: aerodynamic and acoustic measurements. Aerodynamic measurements provide useful information about both the subglottic blowing and the laryngeal functioning. They include many measurements, i.e., maximum phonation time (MPT), the phonatory quotient (PQ), estimated subglottic pressure, and the S/Z ratio. In this paper, we assessed the MPT, PQ, and S/Z ratio using a calibrated spirometer

Fig. 1 Flow chart describing the algorithm for assessment and management of patients. *Asterisk* Patients were excluded if they had infectious, functional, or neurological diseases, history of cervical surgery/radiotherapy, vocal cord paralysis/paresis, malignancy, allergies, or any causes of laryngitis. Active smokers and alcoholics were also excluded



(Spiro-USB100; Medical Electronic Construction, Brussels, Belgium).

Acoustic parameters also assess the vibratory function of the margin of the vocal folds and partially reflect the stability of the vibratory process. Thus, patients were asked to produce the/a/vowel several times, holding the utterance as long as possible. We used the second sample to measure the acoustic assessment including the Jitter percent (Jitt), relative average perturbation (RAP), smoothed pitch perturbation quotient (sPPQ), standard deviation of F0 (STD), shimmer percent (Shim), amplitude perturbation quotient (APQ), smoothed amplitude perturbation quotient (sAPQ), and the noise harmonic ratio (NHR).

Measurements of the acoustic parameters were made on the most stable time interval, 1 s, as defined by the exhibition of the lowest Jitt, Shim, and NHR values (MDVP®, KayPentax, NJ, USA) [20].

Statistical analysis

Statistical analysis was performed using the Statistical Package for the Social Sciences for Windows (SPSS; IBM Corporation, NY, USA). To compare age differences in RSI, RFS, VHI, SF-36, aerodynamic, acoustic measurements, and the proportion of responders at baseline and throughout the treatment period, we used both the median and the

Table 1 Clinical characteristics of patients

	Score, mean (SD)			<i>p</i> value
	18–39 y	40–59 y	>60 y	
	<i>N</i> = 21	<i>N</i> = 31	<i>N</i> = 28	
Mean age (y)	28.43	50.48	69.11	–
BMI (kg/m ²)	24.57	27.68	26.23	0.039
Gender (F/M)	7/14	16/15	10/18	0.509
Treatment respect	6.36	6.57	6.32	0.813
Adverse reactions	0	0	0	1.00
Cured/uncured	12/9	27/4	20/8	0.054
Main complaints				
Globus sensation	5 (23%)	5 (16%)	6 (21%)	
Dysphonia	5 (23%)	4 (13%)	7 (25%)	
Cough	1 (5%)	6 (19%)	4 (14%)	
Odynophagia	4 (19%)	5 (16%)	0	
Heartburn	1 (5%)	3 (10%)	3 (11%)	
Throat clearing	1 (5%)	2 (6%)	4 (14%)	
Dysphagia	1 (5%)	3 (10%)	1 (4%)	
Sticky expectorations/	1 (5%)	1 (3%)	2 (7%)	
Xerostomia	0	0	0	
Postnasal drip	1 (5%)	2 (6%)	0	
Otalgia	1 (5%)	0	0	
Dyspepsia	0	0	1 (4%)	
Breathing difficulties	0	0	0	

F/M female/male, *N* number of subjects, *y* years

Kruskal–Wallis tests. The improvement of these items throughout the treatment was assessed with the Wilcoxon signed-rank test (within group). A level of significance of 0.05 was adopted.

Results

Differences in RSI, RFS, and SF-36 in accordance with age (baseline and after treatment)

Older patients (gr3: more than 60 years) had a significantly lower RSI score at baseline than younger subjects (gr1 and gr2). Among the RSI items, the GERD items were significantly different between groups (Table 2). Our RFS analysis did not reveal a significant difference according to age (Table 2). Within each group, both RSI and RFS significantly improved after treatment without substantial differences among groups (Table 3). Moreover, according to the Kruskal–Wallis test, we found a trend for younger patients to have higher rate of resistant patients than other groups (Table 1).

Concerning the general quality of life, only the social functioning item of SF-36 revealed a significant difference

between groups. Thus, similar to RSI, the oldest subjects had significantly better scores than younger patients (Table 2). The mental health score improved in each group after the treatment period, while the physical score only improved in gr2 (Table 3). The improvement of both physical and mental health scores of SF-36 did not show significant differences between groups (Table 3).

Difference of VHI according to age (baseline and after treatment)

At baseline, we did not find significant differences in the VHI total and item scores between groups according to age. Prospectively, the VHI total score significantly improved in each group without showing a significant difference in accordance with age (Table 4).

Objective voice quality difference in accordance with age at baseline and throughout treatment

At diagnosis, older patients presented lower values of PQ than younger subjects. Simultaneously, the older patient cohort exhibited a lower vital capacity (Table 5). No aerodynamic measurements improved after treatment in all groups.

Concerning the acoustic measurements, at baseline, we found higher values of sAPQ in older patients than in younger patients ($p = 0.039$). However, the other short-term perturbation cues (Shim, APQ, and sAPQ) reported significant improvement after treatment only within the younger groups. We found similar enhancements with the values of Jitt, RAP, sPPQ, and STD (Table 6).

Discussion

LPRD is a causative factor of chronic laryngitis and complaints affecting the quality of life of patients. Since the first work of Koufman et al. [21], only one study investigated the impact of LPRD on the severity of symptoms, signs, voice quality, and quality of life according to age [15]. The main result of our study highlighted that older patients complained less than younger patients at baseline even if they had similar laryngeal signs of chronic laryngitis. This difference was strengthened between the groups on the assessment of heartburn, dyspepsia, and chest pain (GERD complaints). In GERD, the unusual expression of symptoms by elderly patients has already been the subject of previous studies, which showed similar findings compared to ours [14]. Furthermore, several studies reported that the frequency of GERD complications (i.e., esophagitis, stricture, and Barrett esophagus) was substantially higher in elderly than in younger patients [22–25]. A possible explanation

Table 2 Initial RSI, RFS, and SF-36 scores according to age

Scales, items	Score, mean (SD)			
	18–39 years	40–59 years	>60 years	<i>p</i> value
	<i>N</i> = 21	<i>N</i> = 31	<i>N</i> = 28	
RSI	23.94 ± 1.71	23.78 ± 1.50	19.19 ± 1.26	0.035
Voice problem	2.75 ± 0.45	2.74 ± 0.39	2.81 ± 0.38	0.641
Throat clearing	3.44 ± 0.48	4.11 ± 0.28	3.13 ± 0.50	0.193
Postnasal drip	2.94 ± 0.50	3.04 ± 0.37	2.69 ± 0.44	0.734
Dysphagia	2.00 ± 0.49	1.78 ± 0.33	0.94 ± 0.31	0.385
Coughing post-eating and lying down	1.75 ± 0.49	2.30 ± 0.47	1.44 ± 0.34	0.698
Breathing difficulties	1.50 ± 0.42	1.59 ± 0.35	1.38 ± 0.35	0.969
Troublesome cough	2.56 ± 0.46	2.44 ± 0.41	1.94 ± 0.46	0.895
Globus pharyngeus	3.25 ± 0.49	2.89 ± 0.41	2.38 ± 0.50	0.590
Pyrosis, heartburn and chest pain	4.06 ± 0.34	2.78 ± 0.38	2.44 ± 0.47	0.006
RFS	10.00 ± 0.40	11.04 ± 0.46	10.59 ± 0.48	0.195
Subglottic edema	0.04 ± 0.04	0.01 ± 0.01	0.01 ± 0.01	0.485
Ventricular obliteration	1.00 ± 0.32	1.41 ± 0.30	0.75 ± 0.31	0.879
Arytenoid/diffuse redness	3.00 ± 0.26	3.33 ± 0.18	3.25 ± 0.25	0.510
Vocal folds edema	1.13 ± 0.18	1.56 ± 0.13	1.38 ± 0.22	0.357
Diffuse laryngeal edema	1.13 ± 0.22	1.19 ± 0.20	1.06 ± 0.28	0.795
Posterior commissure hypertrophy	2.00 ± 0.16	2.26 ± 0.11	2.13 ± 0.18	0.287
Granuloma/granulation	0.38 ± 0.20	0.30 ± 0.14	0.56 ± 0.22	0.240
Endolaryngeal mucous	1.37 ± 0.24	0.96 ± 0.20	1.50 ± 0.22	0.220
SF36				
Physical functioning	89.69 ± 3.37	80.56 ± 3.00	75.94 ± 6.56	0.127
Role-physical	68.75 ± 8.99	62.04 ± 7.11	56.25 ± 11.52	0.881
Bodily pain	75.19 ± 7.48	68.63 ± 5.86	64.81 ± 6.81	0.329
General health	54.88 ± 4.97	58.81 ± 3.76	63.38 ± 3.67	0.853
Vitality	47.06 ± 5.77	52.52 ± 3.59	57.13 ± 5.23	0.702
Social functioning	72.00 ± 8.34	67.63 ± 4.75	88.38 ± 4.90	0.049
Role-emotional	62.50 ± 10.49	77.70 ± 7.13	77.00 ± 9.01	1.00
Mental health	54.25 ± 4.88	59.44 ± 4.07	63.19 ± 4.91	0.351
Physical health	70.34 ± 20.24	68.11 ± 19.40	65.78 ± 22.82	0.755
Mental health	60.17 ± 26.48	63.49 ± 19.59	70.73 ± 18.80	0.559

RFS reflux finding score, *RSI* reflux symptom index, *SD* standard deviation, *SF-36* Short Form 36 Health Survey

for this result may consist of neurological deterioration of the terminal sensitive nerve ending, especially in the upper aerodigestive tract, leading to a reduction of the symptom's perception. This observation is critical, since, as shown in GERD studies [14], the reduction of the symptom perception encountered in older people suggests that the subjective complaints of this category of patients could be an incorrect indicator of LPRD presence and severity, and may bias the response to PPI treatment. However, our data, which exhibit a higher rate of non-responder patients in younger (42.9%) than in older patients (28.6%), tend to support this hypothesis. These observations may raise questions about the similar application of the current RSI threshold ($RSI > 13$) in all age groups for selecting patients with a high probability of LPRD diagnosis.

To the best of our knowledge, only the study by Lee et al. investigated the effect of age on LPRD signs, symptoms, and quality of life [15]. These authors found that elderly persons could have a higher RSI at baseline than younger subjects, which conflicts with the results of the present study [15]. Various factors may explain the inconsistencies between our results. First, the inclusion process of patients varies between our two studies, since we included patients with both $RSI > 13$ and $RFS > 7$ scores, fully respecting the initial thresholds of Belafsky et al. that suggest a high probability of LPRD [16]. The selection of patients in the study by Lee et al. was based on a physician's diagnosis, irrespective of the well-validated thresholds of both the RSI and RFS scores. This difference represents a potential bias regarding the recruited population

Table 3 Improvement in RSI, RFS, and SF-36 scores after treatment

Test	Score, mean (SD)		<i>p</i> value	
	Baseline	3 months	Within group	Among Groups
RSI				
18–39 years	23.94 ± 1.71	12.05 ± 6.37	<0.001	
40–59 years	23.78 ± 1.50	8.39 ± 6.28	<0.001	0.115
60–79 years	19.19 ± 1.26	7.18 ± 5.00	<0.001	
RFS				
18–39 years	10.00 ± 0.40	4.24 ± 3.00	<0.001	
40–59 years	11.04 ± 0.46	5.26 ± 3.01	<0.001	0.903
60–79 years	10.59 ± 0.48	4.93 ± 3.47	<0.001	
SF-36				
Physical health				
18–39 years	70.34 ± 20.24	77.97 ± 18.43	0.061	
40–59 years	68.11 ± 19.40	78.53 ± 15.45	0.001	0.615
60–79 years	65.78 ± 22.82	72.25 ± 20.16	0.061	
Mental health				
18–39 years	60.17 ± 26.48	72.75 ± 20.79	0.003	
40–59 years	63.49 ± 19.59	76.19 ± 17.26	<0.001	0.465
60–79 years	70.73 ± 18.80	78.83 ± 13.60	0.024	

RFS reflux finding score, RSI reflux symptom index, SD standard deviation, SF-36 Short Form 36 Health Survey

Table 4 Improvement in VHI scores after treatment

Test	Score, mean (SD)		<i>p</i> value	
	Baseline	3 months	Within group	Among groups
VHI				
18–39 years	17.86 ± 12.31	10.67 ± 9.05	0.002	
40–59 years	16.66 ± 13.70	10.63 ± 10.28	0.007	0.313
60–79 years	20.50 ± 17.37	9.77 ± 10.67	<0.001	

SD standard deviation, VHI voice handicap index

Table 5 Initial aerodynamic measures according to age

Aerodynamic measurements	Values, mean (SD)			<i>p</i> value
	18–39 years <i>N</i> = 21	40–59 years <i>N</i> = 31	>60 years <i>N</i> = 28	
MPT	15.84 ± 2.21	14.58 ± 1.05	16.66 ± 2.24	0.194
PQ	283.75 ± 24.86	283.33 ± 20.79	227.38 ± 22.68	0.021 ^a
S/Z	1.08 ± 0.07	1.17 ± 0.14	0.81 ± 0.07	0.177

MPT maximum phonation time, PQ phonatory quotient, S/Z S/Z ratio, SD standard deviation

^aThe vital capacity of each group in the present study was, respectively, 3895.63 ± 291.26 (gr1), 3706.30 ± 165.95 (gr2), and 3167.62 ± 147.46 (gr3), showing a trend to significant difference between groups (*p* = 0.08; Kruskal–Wallis test)

for the study, limiting our inter-study comparison. Second, it has been suggested in the previous studies that the variation of diet according to the world region also impacts the reflux presentation and the values of the RSI at baseline with higher scores in Western areas [16, 18] than in Asian populations [26]. Third, it is possible that other extrinsic

factors may have impacted the laryngeal complaints particularly in the elderly Korean people. Thus, an existing difference between Korea and Belgium (Western Europe) still remains with regard to exposure to fine particles, since the level of fine particles seems to be lower in Belgium than in Korea [27, 28], where the air quality is impacted

Table 6 Improvement of acoustic measurements after treatment

Test	Score, mean (SD)		<i>p</i> value	
	Baseline	3 months	Within group	Among groups
F0 perturbation cues				
Jitt				
18–39 years	1.31 ± 0.75	1.23 ± 0.93	0.002	
40–59 years	1.48 ± 0.15	1.05 ± 0.63	0.033	0.409
60–79 years	1.54 ± 0.31	1.98 ± 3.91	0.790	
RAP				
18–39 years	0.72 ± 0.48	0.74 ± 0.57	0.054	
40–59 years	0.83 ± 0.44	0.62 ± 0.39	0.031	0.386
60–79 years	0.89 ± 0.74	1.20 ± 2.36	0.946	
sPPQ				
18–39 years	0.89 ± 0.43	0.91 ± 0.51	0.520	
40–59 years	1.16 ± 0.11	0.89 ± 0.44	0.027	0.375
60–79 years	1.60 ± 0.26	2.41 ± 5.86	0.853	
STD				
18–39 years	2.31 ± 1.39	2.52 ± 1.75	0.054	
40–59 years	2.60 ± 0.34	1.96 ± 1.02	0.033	0.860
60–79 years	5.53 ± 1.49	4.87 ± 10.12	0.238	
Intensity perturbation cues				
Shim				
18–39 years	4.26 ± 1.83	4.01 ± 1.17	0.520	
40–59 years	5.26 ± 0.43	4.02 ± 1.64	0.001	0.230
60–79 years	4.42 ± 0.51	5.51 ± 4.78	0.258	
APQ				
18–39 years	3.41 ± 1.35	3.33 ± 1.11	0.002	
40–59 years	4.35 ± 0.33	3.18 ± 1.33	<0.001	0.219
60–79 years	5.03 ± 0.48	4.56 ± 3.67	0.191	
sAPQ				
18–39 years	6.36 ± 2.49	6.42 ± 2.65	0.054	
40–59 years	8.59 ± 0.55	6.27 ± 3.89	0.002	0.051
60–79 years	9.20 ± 0.83	9.15 ± 5.44	0.949	
Noise-related measurements				
NHR				
18–39 years	0.13 ± 0.04	0.13 ± 0.02	0.520	
40–59 years	0.14 ± 0.01	0.13 ± 0.02	0.183	0.520
60–79 years	0.14 ± 0.05	0.17 ± 0.16	0.339	

SD standard deviation

by China's pollution [29]. Regarding scientific evidence that suggests an epidemiological relationship between the exposure to fine particles and the development of chronic laryngitis [30], particularly in Korea [31], it is possible that the complaints of elderly subjects reported in the study of Lee et al. may be related to both LPRD and lifelong pollution exposure [30, 31]. Concerning the improvement of RSI and RFS throughout the treatment period, all patient groups reported significant improvement of both signs and symptoms in a similar manner that corroborates the results of Lee et al. [15] and those of many single cohort studies [16, 20, 26]. Thus, age seems to have no effect on the

improvement of symptoms (RSI) and signs (RFS) throughout the treatment period.

The various clinical complaints of LPRD patients are well known to negatively impact the quality of life [4, 5, 32, 33]. In this paper, we observed that elderly patients, who had less laryngeal symptoms, have better scores in social functioning quality of life. However, this discrete result, which only concerns one item on the SF-36 scale, could be reflected by the lower complaints of LPRD (RSI total score) and/or heartburn in the elderly group. These results are in line with other studies demonstrating that laryngeal symptoms related to LPRD significantly impact the social functioning

quality of life of patients [4, 32, 34]. Among them, Lee et al. also observed that the patients with higher RSI scores had lower LPR health-related quality of life scores [15]. Prospectively, the mental health score significantly improved in all groups, while the physical health score only improved in the second group (40–59 years). However, among groups, we did not find significant differences in the improvement of these two scores according to age. Our data reflect those of the current literature since it is well established that LPRD treatment improves the quality of life for LPRD patients [4, 32]. Concerning the improvement of quality of life among groups according to age, Lee et al. observed similar findings, namely, a significant impact of age on the improvement of the quality of life [15].

In addition, regarding the evidences reporting a significant impact of LPRD on voice quality, we aimed to investigate the usefulness of objective voice quality as an outcome of treatment efficiency according to the age. The motivation for this part of study was embodied by the occurrences reporting that older patients have micro- and macrostructural changes in the composition of the vocal fold [35], which may lead to a higher sensitivity to voice disorders, that may also impact the utilization of voice quality as outcome [36, 37]. Moreover, it has recently been suggested that wound healing and inflammation within the vocal fold tissue presumably underlie physiological aging influences [38, 39]. Regarding these recent data, we postulated that elderly patients have a high negative impact of LPRD on voice quality compared to younger subjects. Our study of voice quality reported no difference between groups at the moment of the diagnosis and throughout treatment, concerning both the VHI scores and the improvement of these scores. Concerning the initial aerodynamic evaluations, the lower value of vital capacity in the older group limits the interpretation of the PQ results, since that measure may significantly impact and bias the final results. Acoustically, older patients had higher values of sAPQ, which is an acoustic parameter reflecting the short-term perturbation of the voice intensity. This small difference related to age makes sense prospectively, since we observed better improvement in several acoustic cues (Jitt, RAP, sPPQ, STD, Shim, APQ, and sAPQ) within younger groups (gr1 and gr2) but not in elderly patients (gr3). Several hypotheses may explain these results.

First, we must keep in mind that the RFS score does not take into consideration all signs of LPRD that have a substantial impact on voice quality, especially several chronic signs including vocal fold keratosis, epithelium thickening, and mucosa microtraumatism [5]. In their older age, the elderly patients could present with more of these chronic signs than younger patients who may significantly impact their voice quality. However, several of these signs (keratosis or microtraumatism and the microscars) are known

to need more time to disappear, especially in a context of a slower wound healing process related to age [5]. In addition, in light of the studies supporting that the mucosa of the margin of the vocal folds of the older patients is less resistant to vocal aggression [38, 39], we may suspect that the irritation related to the refluxed content of the stomach (pepsin, trypsin, and other gastroduodenal proteins) could rapidly lead to vocal fold lesions and biomolecular alterations, both decreasing the vibratory biomechanical properties of the vocal folds.

Second, it is probable that many of our older patients have both LPRD and presbyphonia which is more prevalent in people older than 65 years of age [40]. Skeletal, pharmaceutical, hormonal, circulatory, and neuromuscular changes usually occurred in elderly patients and may insidiously impact voice quality [41]. These modifications result in expected age-related acoustic variability, which remains difficult to distinguish from a true voice disorder such as LPRD [41]. In the present study, according to the RFS (vocal fold trophicity and the endolaryngeal mucus thickening items), we determined that the most common video laryngostroboscopic sign found in presbyphonia (i.e., vocal fold atrophy with incomplete glottal closure and dryness of the mucosa) are no more prevalent in older patients than in younger patients [40, 41]. Moreover, our older patients did not have a significantly lower MPT, which is a usual aerodynamic alteration related to incomplete glottal closure observed in aging voice patients [42]. The lack of these differences between our older group and the other groups may support a low rate of presbyphonic patients in our cohort, but it does not exclude the occurrence of both symptoms and signs related to aging voice in our older population. Indeed, beyond the usual signs, aging voice is characterized by laryngeal symptoms, such as dysphonia, throat clearing, and globus sensation that can be misattributed to LPRD [41]. Currently, we cannot say that these two main hypotheses are true; thus, biomolecular studies are needed to investigate these hypotheses.

In this study, we did not record the LPRD events using a multichannel pH monitoring study, since this method still remains controversial and expansive. Moreover, it has been demonstrated that 24-h MII pH monitoring and a combination of RSI and RFS are quite competitive with each other in selecting LPRD patients [43]. Largely for these reasons, the increased management strategy for LPRD patients is based on the clinical response to diet and empirical medical treatment to confirm the diagnosis [10, 11], which is usually very explicit and recommended by both gastroenterology and otolaryngology experts and guidelines. However, our observations raise the question of the utilization of this approach both in the evaluation of the symptoms related to LPRD in elderly patients who often have LPR-like symptoms due to

aging voice. At the end of the empirical period of 3 months, the proportion of responder patients varied, ranging from 41 to 100% according to the previous studies [6, 44]. Our lower rate of non-responders in the older group tends to support the notion that the reliability of the clinical complaints of the elderly patients could be lower than younger patients, ultimately reducing the ability to detect resistant patients. To date, there are three main causes explaining the treatment resistance. The first concerns the poor treatment compliance. Indeed, as showed in the study of Pisenga et al., 62.7% of patients reported an incorrect routine in taking their PPI, since they take it with other pills, with food/drink, and many patients often forget the PPI taking [45]. The second cause involves the biliary LPRD that cannot improve with high doses of PPI, because the increase of pH in the laryngopharyngeal space may improve the destructive activity of trypsin and strengthen the mucosa damage [46, 47]. The third cause is the misdiagnosis of LPRD. Regarding these main causes, the management of resistant patients must at least include a verification of the treatment compliance, the realization of pH impedance monitoring, and the exploration of both differential diagnoses and laryngeal cofactors that could explain the persistence of signs and symptoms (i.e., allergy, exposition of toxic particles, etc.).

Regarding the higher risk of elderly subjects to develop laryngeal cancer favored by LPRD, we need to improve the detection of LPRD resistance to effectively treat the illness. Finally, our report suggests that the usefulness of voice quality as outcome of the treatment efficiency should be done carefully, since many patients have aging voice that may bias the voice quality evaluations.

Conclusion

Elderly patients with LPRD had lower symptom score and better quality of life score than younger patients. These observations, and the lower rate of uncured older patients, put into question the reliability of the symptom's evaluation of elderly patients for both the LPRD diagnosis and the judgment of the treatment efficiency. Moreover, our results suggest that the utilization of voice quality as outcome of the treatment efficiency is less reliable in elderly patients who often suffer from presbyphonia. Further studies with a higher number of patients and precise evaluations of all signs and symptoms of both LPRD and presbyphonia are needed to confirm our results.

Acknowledgements This research has been subsidized by the ARC No. AUWB-2012-12/17-UMONS convention from Communauté Française de Belgique. American Journal Expert for the proofreading of the paper.

References

- Koufman JA, Aviv JE, Casiano RR, Shaw GY (2002) Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. *Otolaryngol Head Neck Surg* 127(1):32–35
- Sen P, Georgalas C, Bhattacharyya AK. A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux. *Clin Otolaryngol*. 2006; 31(1):20-4; discussion 24
- Jin BJ, Lee YS, Jeong SW, Jeong JH, Lee SH, Tae K (2008) Change of acoustic parameters before and after treatment in laryngopharyngeal reflux patients. *Laryngoscope* 118(5):938–941
- Lee JS, Lee YC, Kim SW, Kwon KH, Eun YG (2014) Changes in the quality of life of patients with laryngopharyngeal reflux after treatment. *J Voice* 28(4):487–491
- Lechien JR, Finck C, Costa de Araujo P, Huet K, Delvaux V, Piccaluga M, Harmegnies B, Saussez S (2017) Voice outcomes of laryngopharyngeal reflux treatment: a systematic review of 1483 patients. *Eur Arch Otorhinolaryngol* 274(1):1–23
- Ulualp SO, Toohill RJ, Shaker R (2001) Outcomes of acid suppressive therapy in patients with posterior laryngitis. *Otolaryngol Head Neck Surg* 124(1):16–22
- Lee YS, Choi SH, Son YI, Park YH, Kim SY, Nam SY (2011) Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease. *Eur Arch Otorhinolaryngol* 268(6):863–869
- Sataloff RT, Hawkshaw MJ, Gupta R (2010) Laryngopharyngeal reflux and voice disorders: an overview on disease mechanisms, treatments, and research advances. *Discov Med*. 10(52):213–224
- Noordzij JP, Khidr A, Desper E, Meek RB, Reibel JF, Levine PA (2002) Correlation of pH probe-measured laryngopharyngeal reflux with symptoms and signs of reflux laryngitis. *Laryngoscope* 112(12):2192–2195
- Ford CN (2005) Evaluation and management of laryngopharyngeal reflux. *JAMA* 294(12):1534–1540
- Gupta N, Green RW, Megwalu UC (2016) Evaluation of a laryngopharyngeal reflux management protocol. *Am J Otolaryngol* 37(3):245–250
- Morgan S, Smith H, Simpson I, Liddiard GS, Raphael H, Pickering RM, Mant D (1999) Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. *BMJ* 318(7180):368–372
- Griffin MA, Solomon DH (1986) Hyperthyroidism in the elderly. *J Am Geriatr Soc* 34:887–892
- Morton LS, Fromkes JJ (1993) Gastroesophageal reflux disease: diagnosis and medical therapy. *Geriatrics* 48(3):60–66
- Lee YC, Lee JS, Kim SW, Kwon KH, Eun YG (2013) Influence of age on treatment with proton pump inhibitors in patients with laryngopharyngeal reflux disease: a prospective multicenter study. *JAMA Otolaryngol Head Neck Surg*. 139(12):1291–1295
- Belafsky PC, Postma GN, Koufman JA (2001) The validity and reliability of the reflux finding score (RFS). *Laryngoscope* 111(8):1313–1317
- Koufman JA (2011) Low-acid diet for recalcitrant laryngopharyngeal reflux: therapeutic benefits and their implications. *Ann Otol Rhinol Laryngol*. 120(5):281–287
- Lechien JR, Saussez S, Harmegnies B, Finck C, Burns JA (2017) Laryngopharyngeal reflux and voice disorders: a multifactorial model of etiology and pathophysiology. *J Voice*. doi:10.1016/j.jvoice.2017.03.015
- Woisard V, Bodin S, Puech M (2004) The Voice Handicap Index: impact of the translation in French on the validation. *Rev Laryngol Otol Rhinol (Bord)* 125(5):307–312

20. Lechien JR, Huet K, Khalife M et al (2016) Impact of laryngopharyngeal reflux on subjective and objective voice assessments: a prospective study. *J Otolaryngol Head Neck Surg* 45(1):59
21. Koufman J, Sataloff RT, Toohill R (1996) Laryngopharyngeal reflux: consensus conference report. *J Voice* 10(3):215–216
22. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 112(5):1448–1456
23. Riih   IJ, Impivaara O, Sepp  l   M, Sourander LB (1992) Prevalence and characteristics of symptomatic gastroesophageal reflux disease in the elderly. *J Am Geriatr Soc* 40(12):1209–1211
24. Collen MJ, Abdulian JD, Chen YK (1995) Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy. *Am J Gastroenterol* 90(7):1053–1057
25. el-Serag HB, Sonnenberg A (1997) Associations between different forms of gastro-oesophageal reflux disease. *Gut* 41(5):594–599
26. Li J, Zhang L, Zhang C, Cheng JY, Li J, Jeff Cheng CF (2016) Linguistic adaptation, reliability, validation, and responsiveness of the Chinese version of reflux symptom index. *J Voice* 30(1):104–108
27. Kim HS, Kim DS, Kim H, Yi SM (2012) Relationship between mortality and fine particles during Asian dust, smog-Asian dust, and smog days in Korea. *Int J Environ Health Res* 22(6):518–530
28. Pascal M, de Crouy Chanel P, Wagner V et al (2016) The mortality impacts of fine particles in France. *Sci Total Environ* 571:416–425
29. Kang CM, Kang BW, Lee HS (2006) Source identification and trends in concentrations of gaseous and fine particulate principal species in Seoul, South Korea. *J Air Waste Manag Assoc* 56(7):911–921
30. Ancona C, Badaloni C, Mataloni F et al (2015) Mortality and morbidity in a population exposed to multiple sources of air pollution: a retrospective cohort study using air dispersion models. *Environ Res* 137:467–474
31. Joo YH, Lee SS, Han KD, Park KH (2015) Association between chronic laryngitis and particulate matter based on the Korea National Health and Nutrition Examination Survey 2008–2012. *PLoS One* 10(7):e0133180
32. Siupsinskiene N, Adamonis K, Toohill RJ (2007) Quality of life in laryngopharyngeal reflux patients. *Laryngoscope* 117(3):480–484
33. Karkos PD, Wilson JA (2006) Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review. *Laryngoscope* 116(1):144–148
34. Stull DE, de Jonge PV, Houghton K, Kocun C, Sandor DW (2011) Development of a frequent heartburn index. *Qual Life Res* 20(7):1023–1034
35. Roberts T, Morton R, Al-Ali S (2011) Microstructure of the vocal fold in elderly humans. *Clin Anat* 24(5):544–551
36. Pernambuco L, Espelt A, G  is AC, de Lima KC (2017) Voice disorders in older adults living in nursing homes: prevalence and associated factors. *J Voice* 31(4):510.e15–510.e21
37. Pernambuco L, Espelt A, Costa de Lima K (2017) Screening for voice disorders in older adults (RAVI)-part III: cutoff score and clinical consistency. *J Voice* 31(1):117.e17–117.e22
38. Graupp M, Kiesler K, Friedrich G et al (2014) Vocal fold fibroblast response to growth factor treatment is age dependent: results from an in vitro study. *J Voice* 28(4):420–423
39. Chung HY, Cesari M, Anton S et al (2009) Molecular inflammation: underpinnings of aging and age-related diseases. *Ageing Res Rev* 8:18–30
40. Patel AK, Mildenhall NR, Kim W, Carroll TL (2014) Symptom overlap between laryngopharyngeal reflux and glottic insufficiency in vocal fold atrophy patients. *Ann Otol Rhinol Laryngol* 123(4):265–270
41. Woo P, Casper J, Colton R, Brewer D (1992) Dysphonia in the aging: physiology versus disease. *Laryngoscope* 102:139–144
42. Vaca M, Mora E, Cobeta I (2015) The aging voice: influence of respiratory and laryngeal changes. *Otolaryngol Head Neck Surg* 153(3):409–413
43. Wan Y, Yan Y, Ma F, Wang L, Lu P, Maytag A, Jiang JJ (2014) LPR: how different diagnostic tools shape the outcomes of treatment. *J Voice* 28(3):362–368
44. Vaezi MF (2006) Reflux-induced laryngitis (laryngopharyngeal reflux). *Curr Treat Options Gastroenterol* 9(1):69–74
45. Pisegna JM, Yang S, Purcell A, Rubio A (2017) A mixed-methods study of patient views on reflux symptoms and medication routines. *J Voice* 31(3):381.e15–381.e25
46. Lechien JR, Saussez S, Harmegnies B, Finck C, Burns JA (2017) Laryngopharyngeal reflux and voice disorders: a multifactorial model of etiology and pathophysiology. *J Voice*
47. Lien HC, Wang CC, Lee SW, Hsu JY, Yeh HZ, Ko CW, Chang CS, Liang WM (2015) Responder definition of a patient-reported outcome instrument for laryngopharyngeal reflux based on the US FDA guidance. *Value Health* 18(4):396–403